RU2705156C2 - Таблетки, содержащие большую дозу рукапариба - Google Patents

Таблетки, содержащие большую дозу рукапариба Download PDF

Info

Publication number
RU2705156C2
RU2705156C2 RU2017109139A RU2017109139A RU2705156C2 RU 2705156 C2 RU2705156 C2 RU 2705156C2 RU 2017109139 A RU2017109139 A RU 2017109139A RU 2017109139 A RU2017109139 A RU 2017109139A RU 2705156 C2 RU2705156 C2 RU 2705156C2
Authority
RU
Russia
Prior art keywords
tablet
active pharmaceutical
contained
pharmaceutical ingredient
range
Prior art date
Application number
RU2017109139A
Other languages
English (en)
Russian (ru)
Other versions
RU2017109139A (ru
RU2017109139A3 (https=
Inventor
Джеффри ЭТТЕР
Original Assignee
Кловис Онколоджи, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кловис Онколоджи, Инк. filed Critical Кловис Онколоджи, Инк.
Publication of RU2017109139A publication Critical patent/RU2017109139A/ru
Publication of RU2017109139A3 publication Critical patent/RU2017109139A3/ru
Application granted granted Critical
Publication of RU2705156C2 publication Critical patent/RU2705156C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2017109139A 2014-08-22 2015-08-17 Таблетки, содержащие большую дозу рукапариба RU2705156C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462040849P 2014-08-22 2014-08-22
US62/040,849 2014-08-22
US201562101739P 2015-01-09 2015-01-09
US62/101,739 2015-01-09
PCT/US2015/045522 WO2016028689A1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib

Publications (3)

Publication Number Publication Date
RU2017109139A RU2017109139A (ru) 2018-09-24
RU2017109139A3 RU2017109139A3 (https=) 2019-03-06
RU2705156C2 true RU2705156C2 (ru) 2019-11-05

Family

ID=55347324

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017109139A RU2705156C2 (ru) 2014-08-22 2015-08-17 Таблетки, содержащие большую дозу рукапариба

Country Status (23)

Country Link
US (3) US9987285B2 (https=)
EP (1) EP3182975B1 (https=)
JP (3) JP6574477B2 (https=)
KR (2) KR102803917B1 (https=)
CN (2) CN106794185A (https=)
AU (2) AU2015305696B2 (https=)
BR (1) BR112017000865A2 (https=)
CA (1) CA2955495C (https=)
DK (1) DK3182975T3 (https=)
ES (1) ES3048688T3 (https=)
FI (1) FI3182975T3 (https=)
HR (1) HRP20251484T1 (https=)
IL (1) IL249946B (https=)
LT (1) LT3182975T (https=)
MX (1) MX367260B (https=)
NZ (1) NZ728392A (https=)
PL (1) PL3182975T3 (https=)
PT (1) PT3182975T (https=)
RS (1) RS67356B1 (https=)
RU (1) RU2705156C2 (https=)
SG (1) SG11201700265VA (https=)
SI (1) SI3182975T1 (https=)
WO (1) WO2016028689A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6491669B2 (ja) 2014-02-05 2019-03-27 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｇｒｐ活性化合物の錠剤製剤
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
KR102803917B1 (ko) 2014-08-22 2025-05-07 파르마＆ 슈바이츠 게엠베하 루카파립의 고 용량 강도 정제
CN106008530B (zh) * 2016-07-24 2018-06-26 石家庄久正生物科技有限公司 一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
US10875870B2 (en) 2017-01-24 2020-12-29 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
BR112019020211A2 (pt) 2017-03-27 2020-04-22 Tesaro, Inc. composições de niraparib
KR20250016494A (ko) * 2017-09-26 2025-02-03 테사로, 인코포레이티드 니라파립 제제
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN108853030B (zh) * 2018-09-26 2021-10-01 上海朝晖药业有限公司 一种治疗恶性肿瘤的药物制剂及其制备方法
CN111542527A (zh) * 2018-12-06 2020-08-14 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
CN114341162B (zh) 2019-07-10 2025-10-17 赛博克萨2公司 作为治疗剂的细胞毒素的肽缀合物
TW202116356A (zh) 2019-07-10 2021-05-01 美商斯布雷克薩三號公司 作為治療劑之微管靶向藥劑之肽結合物
EP4143182B1 (en) 2020-04-28 2024-12-11 Rhizen Pharmaceuticals AG Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
EP4182318B1 (en) 2020-07-14 2025-08-27 Assia Chemical Industries Ltd. Solid state forms of rucaparib salts
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
IL307339A (en) 2021-04-08 2023-11-01 Rhizen Pharmaceuticals Ag Poly(ADP-ribose) polymerase inhibitors
WO2023049920A1 (en) 2021-09-27 2023-03-30 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
WO2023086784A1 (en) * 2021-11-10 2023-05-19 Crititech, Inc. Rucaparib particles and uses thereof
WO2023137060A1 (en) 2022-01-11 2023-07-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110136883A1 (en) * 2008-04-09 2011-06-09 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
US20120302550A1 (en) * 2010-02-12 2012-11-29 Pfizer Inc. Salts and polymorphs of 8-fluoro-2--1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA11749A (en) 1999-01-11 2005-07-19 Agouron Pharma Tricyclic inhibitors of poly(adp-ribose)polymerases.
MXPA05010563A (es) 2003-03-31 2005-11-23 Pfizer Sales de los inhibidores triciclicos de las poli(adp-ribosa) polimerasas.
SI1660095T1 (sl) 2003-07-25 2010-05-31 Cancer Rec Tech Ltd Triciklični parp inhibitorji
EP1793830A2 (en) 2004-09-22 2007-06-13 Pfizer, Inc. Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
EP1799685B1 (en) 2004-09-22 2012-03-28 Pfizer Inc. Polymorphic forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
DK1794163T3 (da) 2004-09-22 2010-04-12 Pfizer Fremgangsmåde til fremstilling af poly(ADP-ribose)polymeraseinhibitorer
CA2869309C (en) 2012-04-05 2021-02-09 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
KR102803917B1 (ko) 2014-08-22 2025-05-07 파르마＆ 슈바이츠 게엠베하 루카파립의 고 용량 강도 정제

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110136883A1 (en) * 2008-04-09 2011-06-09 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
US20120302550A1 (en) * 2010-02-12 2012-11-29 Pfizer Inc. Salts and polymorphs of 8-fluoro-2--1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
RU2570198C2 (ru) * 2010-02-12 2015-12-10 Пфайзер Инк. СОЛИ И ПОЛИМОРФЫ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5-ТЕТРАГИДРО-6Н-АЗЕПИНО[5,4,3-cd]ИНДОЛ-6-ОНА

Also Published As

Publication number Publication date
US10130636B2 (en) 2018-11-20
RU2017109139A (ru) 2018-09-24
US20190099430A1 (en) 2019-04-04
JP6797980B2 (ja) 2020-12-09
ES3048688T3 (en) 2025-12-11
CA2955495C (en) 2023-09-19
CN106794185A (zh) 2017-05-31
JP7127101B2 (ja) 2022-08-29
SG11201700265VA (en) 2017-02-27
MX367260B (es) 2019-08-12
NZ728392A (en) 2023-06-30
PT3182975T (pt) 2025-10-28
KR20230097211A (ko) 2023-06-30
AU2015305696A1 (en) 2017-02-02
RS67356B1 (sr) 2025-11-28
EP3182975A1 (en) 2017-06-28
JP2017525712A (ja) 2017-09-07
AU2019272064A1 (en) 2019-12-19
RU2017109139A3 (https=) 2019-03-06
IL249946A0 (en) 2017-03-30
JP2020002149A (ja) 2020-01-09
LT3182975T (lt) 2025-11-25
PL3182975T3 (pl) 2026-02-23
MX2017001540A (es) 2017-05-11
EP3182975A4 (en) 2018-04-18
HRP20251484T1 (hr) 2026-01-02
US20160051561A1 (en) 2016-02-25
KR102803917B1 (ko) 2025-05-07
CA2955495A1 (en) 2016-02-25
AU2015305696B2 (en) 2019-08-29
JP6574477B2 (ja) 2019-09-11
US9987285B2 (en) 2018-06-05
SI3182975T1 (sl) 2025-12-31
US20180200260A1 (en) 2018-07-19
EP3182975B1 (en) 2025-10-01
AU2019272064B2 (en) 2021-11-18
DK3182975T3 (da) 2025-10-20
IL249946B (en) 2020-05-31
FI3182975T3 (fi) 2025-11-13
KR20170043597A (ko) 2017-04-21
JP2021038242A (ja) 2021-03-11
CN113209033A (zh) 2021-08-06
WO2016028689A1 (en) 2016-02-25
BR112017000865A2 (pt) 2017-12-05

Similar Documents

Publication Publication Date Title
RU2705156C2 (ru) Таблетки, содержащие большую дозу рукапариба
RU2456989C2 (ru) Твердые лекарственные формы, содержащие тадалафил
KR100634253B1 (ko) 초강력 붕해제를 사용한 고속-용해 에파비렌즈 캡슐 또는정제 및 그의 제조 방법
KR100202154B1 (ko) 파라세타몰 및 돔페리돈을 함유한 필름 피복 정제
WO2016020080A1 (en) Pharmaceutical compositions of edoxaban
TWI418370B (zh) 溶出安定性製劑
KR20160002177A (ko) 오셀타미비어 유리염기를 포함하는 약학 조성물
JP2016539110A (ja) イソニアジドの顆粒およびリファペンチンの顆粒を含む分散性錠剤の形態の抗結核性の安定な医薬組成物ならびにその製造方法
JP7336528B2 (ja) ネフォパムおよびアセトアミノフェンを含む薬学的組成物の製造方法、およびそれによって得られる薬学的組成物
KR102102462B1 (ko) 오셀타미비어 유리염기를 포함하는 약학 조성물
EP3079672B1 (en) Pharmaceutical composition comprising a pharmaceutically acceptable salt of rasagiline
EP3784218A1 (en) Tablet compositions comprising abiraterone acetate
EP4401708A1 (en) Pharmaceutical composition of bempedoic acid
EA051960B1 (ru) Фармацевтическая композиция бемпедоевой кислоты
HK1232807A1 (en) High dosage strength tablets of rucaparib
HK1232807B (en) High dosage strength tablets of rucaparib
EP3272348A1 (en) Pharmaceutical composition comprising idelalisib